1. FIRST DRAFT OF THE RETROSPECTIVE STUDY Workshop MEDICEL The Mediterranean Network for Celiac Disease III Progress Meeting PastaTrend, BolognaFiere Bologna, April 5th 2011

2. RETROSPECTIVE STUDY AIM: To evaluate the presence of the markers required for the new ESPGHAN protocol in 50 unselected consecutive patients in each country 10 countries: Albania, Bosnia H, Croatia, France, Greece, Italy (Naples), Italy (Sicily), Morocco, Slovenia, Turkey ESPECTED RESULTS: To estimate the percentage of patients who bear the markers required by the new approach To produce a quite original picture of the CD diagnosis in the area 498 cases

3. DATA REQUIRED Date of birth Date of diagnosis Sex Biopsy results Anti TGase (UI) HLA genotype 3 symptoms Familiarity Associated disease Treatment

4. F:M = 2:1 35,5% 64,5% SEX

5. AGE AT DIAGNOSIS 46,5% 32% 16,6% 4,9% 0-4 y 5-9 y10-14 y15-22 y

6. AGE AT DIAGNOSIS/COUNTRY 0-4 y 5-9 y 10-14 y 15-22 y

7. 74% 6,7% 16,3% 2,8% 64,4% NOT Genotyped

8. FAMILIARITY 28,2% 30,6% 17,7% 23,4% FrequencyPercent % Familiarity12825,7 NO Familiarity 37074,3

9. ASSOCIATED DISEASES 11,4% 2,4% 1,8% 4,8% 0,6% 1,6% 0,4% 3,6% 73,3% No associated diseases

10. SYMPTOMS ONLY 22 ASYMPTOMATICS It is a SYMPTOMATIC CD No differences between Males and Females

11. BIOPSY RESULTS NOT DONE = 7,6% 3% 4,3% 7% 14,3% 23,7% 45,7%

12. ANTI-TGASE LEVELS AND BIOPSY

13. NO Atrophy Atrophy ANTI-TGASE LEVELS AND BIOPSY <50 UI50-100 UI>100 UI

14. LIMITATIONS 1.Selection bias 2.Bad management of the missing data: Uncompleted files 3.Anti TGase: Meaning of the NEGATIVE results Lack of standardization 4.Biopsy: Lack of standardization

15. LIMITATIONS

16. FUTURE PROSPECTS Prospective study for 6 months (50 cases/country) to evaluate the applicability of the new ESPGHAN protocol A positive evaluation of the new protocol could reduce the confinement of the diagnosis to specialized centres only

17. THANK YOU